Tine Schytte

Chief physician, Associate professor, PhD Department of Oncology, Odense University Hospital tine.schytte@rsyd.dk
Research interests

DK: Stråleterapi for lungekræft, effekt og toksicitet. Stråleterapi for oligometastisk sygdom. Stråleterapi for bugspytkirtelskræft. Behandling af MR acc. Hjertegift.

UK: Radiotherapy for lung cancer, effect and toxicity. Radiotherapy for oligometastatic disease. Radiotherapy for pancreatic cancer. Treatment on MR acc. Cardiotoxicity.

 Workgroups Publications
  • Bernchou U, Christiansen RL, Bertelsen A, Tilly D, Riis HL, Jensen HR, Mahmood F, Hansen CR, Hansen VN, Schytte T, Brink C End-to-end validation of the geometric dose delivery performance of MR linac adaptive radiotherapy Phys Med Biol . 2021 Feb 12;66(4):045034 2021
  • Christiansen RL, Dysager L, Hansen CR, Jensen HR, Schytte T, Nyborg CJ, Bertelsen AS, Agergaard SN, Mahmood F, Hansen S, Hansen O, Brink C, Bernchou U Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment Radiother Oncol . 2022 Feb;167:165-171 2022
  • Brink C, Bernchou U, Bertelsen A, Hansen O, Schytte T, Hjelmborg JVB, Holloway L, van Herk M, Johnson-Hart C, Price GJ, Aznar MC, McWilliam A, Faivre-Finn C, Hansen CR Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy Radiother Oncol . 2022 Jul;172:126-133 2022
  • Bisgaard ALH, Brink C, Fransen ML, Schytte T, Behrens CP, Vogelius I, Nissen HD, Mahmood F Robust extraction of biological information from diffusion-weighted magnetic resonance imaging during radiotherapy using semi-automatic delineation Phys Imaging Radiat Oncol. 2022 Mar 7;21:146-152 2022
  • Milo MLH, Offersen BV, Bechmann T, Diederichsen ACP, Hansen CR, Holtved E, Josipovic M, Lörincz T, Maraldo MV, Nielsen MH, Nordsmark M, Nyström PW, Pøhl M, Rose HK, Schytte T, Yates ES, Lorenzen EL Delineation of whole heart and substructures in thoracic radiation therapy: National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups. Radiother Oncol . 2020 Jun 13;150:121-127. 2020
  • Bertelsen AS, Schytte T, Møller PK, Mahmood F, Riis HL, Gottlieb KL, Agergaard SN, Dysager L, Hansen O, Gornitzka J, Veldhuizen E, ODwyer DB, Christiansen RL, Nielsen M, Jensen HR, Brink C, Bernchou U First clinical experiences with a high field 1.5 T MR linac. Acta Oncol. 2019 Oct;58(10):1352-1357. 2019
  • Hoffmann L, Persson GF, Nygård L, Nielsen TB, Borrisova S, Gaard-Petersen F, Josipovic M, Khalil AA, Kjeldsen R, Knap MM, Kristiansen C, Møller DS, Ottosson W, Sand H, Thing R, Pøhl M, Schytte T Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours Radiother Oncol . 2022 Jun;171:53-61 2022
  • Hasler SW, Bernchou U, Bertelsen A, van Veldhuizen E, Schytte T, Hansen VN, Brink C, Mahmood F Tumor-site specific geometric distortions in high field integrated magnetic resonance linear accelerator radiotherapy Phys Imaging Radiat Oncol . 2020 Aug 19;15:100-104 2020
  • Jeppesen SS, Hansen NCG, Schytte T, Hansen O Survival of localized NSCLC patients without active treatment or treated with SBRT Acta Oncol. 2018 Feb;57(2):219-225 2018
  • Jeppesen SS, Matzen LE, Brink C, Bliucukiene R, Kasch S, Schytte T, Kristiansen C, Hansen O Impact of comprehensive geriatric assessment on quality of life, overall survival, and unplanned admission in patients with non-small cell lung cancer treated with stereotactic body radiotherapy J Geriatr Oncol. 2018 Nov;9(6):575-582 2018
  • Hansen O, Kristiansen C, Nielsen M, Schytte T, Starup Jeppesen S Survival after stereotactic radiotherapy in patients with early-stage non-small cell lung cancer Acta Oncol. 2019 Oct;58(10):1399-1403 2019
  • Jørgensen N, Meline EL, Jeppesen SS, Hansen O, Nielsen M, Schytte T. The effect of tumor laterality on survival for non-small cell lung cancer patients treated with radiotherapy. Acta Oncol. 2019 Oct;58(10):1393-1398 2019
  • Nielsen M, Kristiansen C, Schytte T, Hansen O Initial experiences with hippocampus-sparing whole-brain radiotherapy for lung cancer patients. Acta Oncol. 2019 Oct;58(10):1540-1542 2019
  • Lutz CM, Knap MM, Hoffmann L, Møller DS, Hansen O, Brink C, Schytte T, Nyhus CH, McCulloch T, Borissova S, Alber M, Khalil AA Prospectively scored pulmonary toxicities in non-small cell lung cancer: Results from a randomized phase II dose escalation trial Clin Transl Radiat Oncol. 2020 Nov 26;27:8-14 2020
  • Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial Lancet Oncol. 2021 Mar;22(3):321-331 2021
  • Møller PK, Pappot H, Bernchou U, Schytte T, Dieperink KB Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy. J Patient Rep Outcomes. 2021 Jun 23;5(1):47 2021
  • Møller PK, Pappot H, Bernchou U, Schytte T, Mortensen ZV, Brúnni MFÁ, Dieperink KB Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy - A prospective pilot study Tech Innov Patient Support Radiat Oncol. 2021 Dec 15;21:8-15 2021
  • Nielsen TB, Brink C, Jeppesen SS, Schytte T, Hansen O, Nielsen M. umour motion analysis from planning to end of treatment course for a large cohort of peripheral lung SBRT targets Acta Oncol. 2021 Nov;60(11):1407-1412 2021
  • Bertelsen A, Bernchou U, Schytte T, Brink C, Mahmood F The effect of respiration-induced target motion on 3D magnetic resonance images used to guide radiotherapy Phys Imaging Radiat Oncol. 2022 Nov 15;24:167-172 2022
  • Killingberg KT, Halvorsen TO, Fløtten Ø, Brustugun OT, Langer SW, Nyman J, Hornslien K, Madebo T, Schytte T, Risum S, Tsakonas G, Engleson J, Grønberg BH Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer Lung Cancer. 2022 Apr;166:49-57 2022
  • Janssen TM, Aitken K, Alongi F, Barry A, Bernchou U, Boeke S, Hall WA, Hosni A, Kroon PS, Nachbar M, Saeed H, Jürgenliemk-Schulz IM, Schytte T, Verkooijen HM, Nowee ME; tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac Tech Innov Patient Support Radiat Oncol. 2022 May 10;22:50-54 2022
  • Held MK, Hansen O, Schytte T, Hansen KH, Bahij R, Nielsen M, Nielsen TB, Jeppesen SS Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain Acta Oncol. 2022 Feb;61(2):185-192 2022
  • Hansen O, Boes MB, Schytte T, Nielsen TB, Jeppesen SS, Nielsen M Survival after palliative radiotherapy in nondisseminated nonsmall cell lung cancer treated with 30 Gy in 10 fractions or 39 Gy in 13 fractions using conformal technique Acta Oncol. 2022 Feb;61(2):193-196 2022